Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $57.00 price target on the stock.
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference [Yahoo! Finance]
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
Supernus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]